Regeneron Pharmaceuticals, Inc. (REGN)
Market Cap | 105.41B |
Revenue (ttm) | 13.12B |
Net Income (ttm) | 3.95B |
Shares Out | 107.94M |
EPS (ttm) | 34.77 |
PE Ratio | 27.68 |
Forward PE | 21.08 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 446,659 |
Open | 970.38 |
Previous Close | 966.30 |
Day's Range | 959.18 - 970.79 |
52-Week Range | 684.81 - 998.33 |
Beta | 0.11 |
Analysts | Buy |
Price Target | 965.52 (+0.31%) |
Earnings Date | May 2, 2024 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2023, REGN's revenue was $13.12 billion, an increase of 7.76% compared to the previous year's $12.17 billion. Earnings were $3.95 billion, a decrease of -8.87%.
Financial StatementsAnalyst Forecast
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $965.52, which is an increase of 0.31% from the latest price.
News
US FDA declines to approve Regeneron's blood cancer therapy
Regeneron Pharmaceuticals said on Monday the U.S. FDA has declined to approve its blood cancer therapy for two most common subtypes of non-Hodgkin lymphoma due to an issue related to enrollment of its...
Regeneron Provides Update on Biologics License Application for Odronextamab
TARRYTOWN, N.Y., March 25, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued Complete Response Letters...
US appeals court revives Regeneron's antitrust lawsuit against Novartis
A U.S. appeals court on Monday revived an antitrust lawsuit by Regeneron Pharmaceuticals against Novartis related to prescription treatments to address a condition that can lead to eye disorders inclu...
Calls of the Day: Regeneron, Thermo Fisher, Darden Restaurants and Nucor
The Investment Committee debate the latest calls of the day on a number of stocks.
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
$250,000 top award goes to Achyuta Rajaram in the nation's oldest and most prestigious Science, Technology, Engineering and Math (STEM) competition for high school seniors TARRYTOWN, N.Y. and WASHING...
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
Approval extends treatment of Praluent to children aged 8 and older with heterozygous familial hypercholesterolemia (HeFH) Approval extends treatment of Praluent to children aged 8 and older with hete...
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA ® (aflibercept) Injection 2 mg with fixed 8-week dosing in...
GENESIS Pharma Announces an Exclusive Distribution Agreement With Regeneron Pharmaceuticals to Commercialize cemiplimab in Greece, Cyprus and Malta
ATHENS, Greece--(BUSINESS WIRE)--GENESIS Pharma announces an exclusive distribution agreement with Regeneron Pharmaceuticals to commercialize cemiplimab in Greece, Cyprus and Malta.
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Priority Review granted based on positive results from two Phase 3 trials; i f approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for this disease in m...
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Dupixent ® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
TARRYTOWN, N.Y., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the ...
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Japan first in the world to approve Dupixent ® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to pl...
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dup...
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron beats quarterly revenue estimates
Drug maker Regeneron beat fourth-quarter revenue estimates on Friday.
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2023 and provided a business up...
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
TARRYTOWN, N.Y., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authori...
2seventy bio to sell experimental cell therapies to Regeneron
Cancer treatment maker 2seventy bio will sell all its experimental cell therapies to Regeneron Pharmaceuticals for an upfront payment of $5 million and focus on its sole approved product Abecma, the t...
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
Regeneron to assume full development and commercialization rights for 2seventy bio's preclinical and clinical stage cell therapy pipeline Regeneron to assume full development and commercialization rig...
US FDA approves Dupixent to treat younger kids with esophageal condition
The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, t...
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Dupixent ® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proporti...
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) TARRYTOWN, N.Y. and WASHINGTON , Jan. 24, 2024 /PRNewswire...
Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Data included from first and only Phase 3 trial specifically evaluating a biologic in this difficult-to-treat population Phase 3 trial showed more than twice as many patients treated with Dupixent ach...